{"id":"nk-1r-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NK-1 receptor antagonists competitively bind to neurokinin-1 receptors in the central and peripheral nervous system, blocking the neuropeptide substance P. This mechanism is particularly effective for chemotherapy-induced nausea and vomiting (CINV) and may have analgesic and anxiolytic properties through modulation of pain and emotional processing pathways.","oneSentence":"NK-1R antagonists block neurokinin-1 receptors to inhibit substance P signaling, reducing nausea, vomiting, and pain perception.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:31.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Post-operative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT06780085","phase":"PHASE2","title":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":96},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT07405151","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-11","conditions":"Oesophageal Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT05653310","phase":"PHASE2","title":"Tradipitant for Functional Dyspepsia","status":"ENROLLING_BY_INVITATION","sponsor":"Xiao Jing (Iris) Wang","startDate":"2023-02-09","conditions":"Functional Dyspepsia","enrollment":60},{"nctId":"NCT04474990","phase":"","title":"Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","status":"AVAILABLE","sponsor":"Vanda Pharmaceuticals","startDate":"","conditions":"Gastroparesis, Diabetic Gastroparesis","enrollment":""},{"nctId":"NCT04028492","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2019-08-20","conditions":"Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis","enrollment":992},{"nctId":"NCT06317064","phase":"PHASE3","title":"Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Lahore Medical Research Center, LLP","startDate":"2024-03-15","conditions":"Primary Dysmenorrhea","enrollment":40},{"nctId":"NCT06836557","phase":"PHASE3","title":"Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","status":"RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2024-01-09","conditions":"Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis","enrollment":100},{"nctId":"NCT04849559","phase":"PHASE1, PHASE2","title":"Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2021-02-01","conditions":"Healthy Volunteer","enrollment":27},{"nctId":"NCT06314906","phase":"PHASE3","title":"Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Feixue Song","startDate":"2024-03-07","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT03649230","phase":"","title":"Observational Study on the Use of Akynzeo® in Patients Receiving HEC","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2018-10-03","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":207},{"nctId":"NCT01951274","phase":"PHASE2","title":"VPD-737 for Treatment of Chronic Pruritus","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2013-10-15","conditions":"Chronic Pruritus","enrollment":257},{"nctId":"NCT05258461","phase":"NA","title":"An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-03-07","conditions":"Breast Cancer","enrollment":108},{"nctId":"NCT02196324","phase":"PHASE2","title":"A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2014-07-09","conditions":"Prurigo Nodularis","enrollment":128},{"nctId":"NCT04468646","phase":"PHASE3","title":"To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients","status":"UNKNOWN","sponsor":"Prof. Dr. Fridoon Jawad Ahmad","startDate":"2020-06-15","conditions":"Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus","enrollment":100},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT00601172","phase":"PHASE3","title":"A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-10","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":710},{"nctId":"NCT02154360","phase":"PHASE1","title":"Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-05","conditions":"HIV Infection","enrollment":12},{"nctId":"NCT00440128","phase":"PHASE1","title":"The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-04","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":12},{"nctId":"NCT02210195","phase":"PHASE2","title":"Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2014-09-04","conditions":"Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder","enrollment":20},{"nctId":"NCT00321477","phase":"PHASE2","title":"A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder","enrollment":160},{"nctId":"NCT00274690","phase":"PHASE2","title":"Post-Operative Nausea And Vomiting Study In Female Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative","enrollment":435},{"nctId":"NCT00394056","phase":"PHASE2","title":"Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Tinnitus","enrollment":26},{"nctId":"NCT00896038","phase":"PHASE2","title":"The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2009-05","conditions":"Alcoholism, Alcohol Dependence, Posttraumatic Stress Disorder","enrollment":58},{"nctId":"NCT01204723","phase":"PHASE1","title":"Medications Development for the Treatment of Cannabis Related Disorders","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2009-08","conditions":"Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence","enrollment":63},{"nctId":"NCT00888329","phase":"PHASE4","title":"Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-07","conditions":"Postoperative Nausea and Vomiting","enrollment":256},{"nctId":"NCT00547612","phase":"PHASE1","title":"Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-09","conditions":"Pancreatic Cancer","enrollment":33},{"nctId":"NCT01440673","phase":"NA","title":"Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2010-03","conditions":"Postoperative Nausea and Vomiting","enrollment":150},{"nctId":"NCT00310427","phase":"PHASE2","title":"Effect of LY686017 on Alcohol Craving","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2006-03","conditions":"Alcohol Dependence, Alcoholism","enrollment":66},{"nctId":"NCT00335660","phase":"PHASE2","title":"Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity","status":"TERMINATED","sponsor":"Avera Pharmaceuticals","startDate":"2006-06","conditions":"Overactive Bladder Syndrome","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NK-1R antagonist","genericName":"NK-1R antagonist","companyName":"Prof. Dr. Fridoon Jawad Ahmad","companyId":"prof-dr-fridoon-jawad-ahmad","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NK-1R antagonists block neurokinin-1 receptors to inhibit substance P signaling, reducing nausea, vomiting, and pain perception. Used for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}